BaldassarreSteaMDFASTRO(He/Him)
Radiation Oncology • Tucson, AZCentral Nervous System Cancer, Melanoma, Ocular Radiation Oncology, Pediatric Radiation Oncology
Professor and Head of the Department Univeristy of Arizona
Dr. Stea is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3838 N Campbell Ave
Bldg 2
Tucson, AZ 85719Phone+1 520-694-8888Fax+1 520-694-0502
Summary
- Dr. Baldassarre Stea is a radiation oncologist in Tucson, AZ and is affiliated with multiple hospitals in the area, including Carondelet St. Joseph's Hospital, Banner - University Medical Center Tucson, and Tucson VA Medical Center. He received his medical degree from George Washington University School of Medicine and has been in practice 34 years. He also speaks multiple languages, including Spanish, French, and Italian. He specializes in central nervous system cancer, melanoma, ocular radiation oncology, and pediatric radiation oncology. He has more than 80 publications and over 500 citings.
Education & Training
National Capital ConsortiumResidency, Radiation Oncology, 1984 - 1987
George Washington UniversityInternship, Internal Medicine, 1983 - 1984- George Washington University School of Medicine and Health SciencesClass of 1983
Certifications & Licensure
AZ State Medical License 1987 - 2025- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- Top Doctors:Arizona State Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
Clinical Trials
- S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma Start of enrollment: 2004 Feb 01
- Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain Start of enrollment: 2008 Nov 01
- Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM Start of enrollment: 2020 Dec 08
Roles: Contact
Publications & Presentations
PubMed
- 436 citationsHippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.Paul D. Brown, Vinai Gondi, Stephanie L. Pugh, Wolfgang A. Tomé, Jeffrey S. Wefel
Journal of Clinical Oncology. 2020-02-14 - 16 citationsTreatment of pelvic sarcomas in adolescents and young adults with intensive combined modality therapyBaldassarre Stea, Timothy J. Kinsella, Timothy J. Triche, K Horvath, Eli Glatstein
International Journal of Radiation Oncology, Biology, Physics. 1987-12-01 - 41 citationsPhase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.James W Welsh, Ritsuko Komaki, Arya Amini, Mark F Munsell, Wyatt Unger
Journal of Clinical Oncology. 2013-03-01
Press Mentions
NuvOx Pharma to Be Honored with 2017 AZBio Fast Lane AwardAugust 28th, 2017
FDA Allows NuvOx Pharma to Run a Phase II Clinical Trial in Brain CancerApril 13th, 2017
Baldassarre SteaNovember 12th, 2016
Professional Memberships
- Member
- Fellow
Other Languages
- Spanish, French, Italian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
